Day One Biopharmaceuticals, Inc. (DAWN)

Market Cap	966.18M
Revenue (ttm)	133.67M
Net Income (ttm)	-151.76M
Shares Out	102.68M
EPS (ttm)	-1.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,313,349
Open	9.35
Previous Close	9.43
Day's Range	9.22 - 9.44
52-Week Range	5.64 - 14.46
Beta	-1.25
Analysts	Strong Buy
Price Target	26.56 (+182.25%)
Earnings Date	Nov 4, 2025

About DAWN

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2021
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: DAWN
• Website: https://dayonebio.com

Analyst Summary

According to 9 analysts, the average rating for DAWN stock is "Strong Buy." The 12-month stock price target is $26.56, which is an increase of 182.25% from the latest price.

Price Target

$26.56

(182.25% upside)

Analyst Consensus: Strong Buy